Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

BACKGROUND: NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles of Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET. The present study evaluates the outcome of further PRRT cycles in the so called salvage setting in patients after initial response...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Rudisile, S., Gosewisch, A., Wenter, V., Unterrainer, M., Böning, G., Gildehaus, F. J., Fendler, W. P., Auernhammer, C. J., Spitzweg, C., Bartenstein, P., Todica, A., Ilhan, H.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6686531/
https://ncbi.nlm.nih.gov/pubmed/31395036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6000-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados